checkAd
    Startseite > Aktien > Travere Thereapeutics > Nachrichten
    Travere Thereapeutics Aktie
    7,4200
     
    USD
    +5,70 %
    +0,4000 USD
    Letzter Kurs 02:00:00 Nasdaq
    7,4100
     
    USD
    100 STK
    Geldkurs 31.05.24
    7,4200
     
    USD
    300 STK
    Briefkurs 31.05.24
    ISIN: US89422G1076 · WKN: A2QHYP · SYM: TVTX · USA

    Neueste Nachrichten

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    15.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
    09.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present at Upcoming Investor Conferences
    08.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics Reports First Quarter 2024 Financial Results
    06.05.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Report First Quarter 2024 Financial Results
    29.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy
    24.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
    04.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
    03.04.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    13.03.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
    11.03.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics to Present at Upcoming Investor Conferences
    26.02.24 · globenewswire · Travere Thereapeutics
    Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
    23.02.24 · globenewswire · Travere Thereapeutics